The complaint filed against the New York-based firm claims that Zoetis misled the market about the true status of its veterinary pharmaceutical portfolio throughout the specified class period. Plaintiffs allege that the company failed to disclose significant challenges affecting key products, causing potential financial harm to shareholders.

The DJS Law Group is currently organizing the litigation and seeking potential lead plaintiffs to represent the class. Shareholders interested in participating or inquiring about their legal rights are encouraged to contact the firm directly before the late-July cutoff. Participation as a lead plaintiff is optional, and individual investors may still be eligible for recovery without assuming a formal leadership role in the proceedings.